In contrast to the Bayer Group, the biopharmaceutical company, led by Max Herzberg, one of the founding fathers of the Israeli life sciences industry, is doing extremely well. The Company's approach is revolutionary. Vidac Pharma is developing anti-cancer drugs by altering the tumor's hyperglycolytic microenvironment and targeting the overexpression and mis-anchoring of the metabolic checkpoint hexokinase 2 in cancer cells to alter the tumor's microenvironment and selectively induce its programmed death without affecting the surrounding normal tissues.
News & Events